Biologics are more potent than other treatment modalities for improvement of quality of life in psoriasis patients

Journal of Dermatology

Volumn 41, Issue 8, 2014, Pages 686-689

  Takahashi, Hidetoshi ^a   Iinuma, Shin ^a   Tsuji, Hitomi ^a   Honma, Masaru ^a   Iizuka, Hajime ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

biologics; Dermatological Life Quality Index; General Health Questionnaire 30; Psoriasis; Psoriasis Area and Severity Index

Indexed keywords

ADALIMUMAB; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN A; ETRETINATE; INFLIXIMAB; USTEKINUMAB; BIOLOGICAL PRODUCT;

ADULT; ANXIETY; ARTICLE; DEPRESSION; DERMATOLOGICAL LIFE QUALITY INDEX; DISEASE SEVERITY; DYSPHORIA; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHOTOTHERAPY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSYCHOSOMATIC DISORDER; QUALITY OF LIFE; SLEEP DISORDER; SOCIAL DISABILITY; SUICIDAL BEHAVIOR; AGED; HEALTH STATUS INDICATOR; MIDDLE AGED; PATHOLOGY; PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADULT; AGED; BIOLOGICAL PRODUCTS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84905683410     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12544     Document Type: Article

References (16)

1. Finlay AY, Kelly SE,. Psoriasis-an index of disability. Clin Exp Dermatol 1987; 12: 8-11.
2. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM,. Psoriasis causes as much disability as other medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
3. Nemoto O, Nakagawa H, Igarashi A, et al,. The results of a satisfaction survey concerning treatment for psoriasis patients. Jpn J Dermatol 2003; 113: 2059-2069.
4. Okubo Y, Natsume S, Usui K, Amaya M, Tsuboi R,. Loe-dose, short-term ciclosporin (Neoral) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients. J Dermatol 2011; 38: 465-472.
5. Sanborn DE III, Sandborn CJ, Cimbolic P, Niswander GD,. Suicide and stress-related dermatosis. Dis Nerv Syst 1972; 33: 391-394.
6. Kiliç A, Güleç MY, Gül U, Güleç Ü,. Temperament and character profile of patients with psoriasis. J Eur Acad Dermatol Venereol 2008; 22: 537-542.
7. Morse RM, Perry HO, Hurt RD,. Alcoholism and psoriasis. Alcoholism 1972; 9: 396-399.
8. Takahashi H, Tsuji H, Honma M, Shibaki H, Ishida-Yamamoto A, Iizuka H,. Patients with psoriasis and atopic dermatitis show distinct anxiety profiles. J Dermatol 2012; 39: 955-956.
9. Van der Kerkhof PC,. The Psoriasis and Area and Severity Index and alternative approaches for the assessment of severity: persisting areas of confusion. Br J Dermatol 1997; 137: 661-662.
10. Both H, Essink-Bot ML, Busschbach J, et al,. Critical review of generic and dermatology-specific health quality of life instruments. J Invest Dermatol 2007; 127: 2726-2739.
11. Goldberg DP, Blackwell B,. Psychiatric illness in general practice. A detailed study using a new methods of case identification. Br Med J 1970; 2: 439-443.
12. Goldberg DP, Hiller VF,. A scaled version of the General Health Questionnaire. Psychol Med 1979; 9: 139-145.
13. Finlay AY,. Current severe psoriasis and rule of tens. Br J Dermatol 2005; 152: 861-867.
14. Lin VW, Ringold S, Devine EB,. Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis. Arch Dermatol 2012; 148: 1403-1410.
15. Vardy D, Besser A, Amir M, et al,. Experience of stigmatization play a role in mediating the impact of disease severity on quality of life in psoriasis patients. Br J Dermatol 2002; 147: 736-742.
16. Nakagawa Y, Oubou I,. Nipponbunnkakagakusha, 1985; 1-7 (in Japanese).